These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14708714)

  • 61. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents.
    Sernee MF; Ploegh HL; Schust DJ
    Mol Immunol; 1998 Feb; 35(3):177-88. PubMed ID: 9694518
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HLA-G: from biology to clinical benefits.
    Carosella ED; Moreau P; Lemaoult J; Rouas-Freiss N
    Trends Immunol; 2008 Mar; 29(3):125-32. PubMed ID: 18249584
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HLA-G expression in malignant melanoma.
    Rebmann V; Wagner S; Grosse-Wilde H
    Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Structure, expression and function of HLA-G in renal cell carcinoma.
    Seliger B; Schlaf G
    Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
    [TBL] [Abstract][Full Text] [Related]  

  • 65. HLA-G truncated isoforms can substitute for HLA-G1 in fetal survival.
    Menier C; Riteau B; Dausset J; Carosella ED; Rouas-Freiss N
    Hum Immunol; 2000 Nov; 61(11):1118-25. PubMed ID: 11137216
    [TBL] [Abstract][Full Text] [Related]  

  • 66. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications.
    Hviid TV
    Hum Reprod Update; 2006; 12(3):209-32. PubMed ID: 16280356
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HLA-G: a shield against inflammatory aggression.
    Carosella ED; Moreau P; Aractingi S; Rouas-Freiss N
    Trends Immunol; 2001 Oct; 22(10):553-5. PubMed ID: 11574278
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Blastocyst MHC, a putative murine homologue of HLA-G, protects TAP-deficient tumor cells from natural killer cell-mediated rejection in vivo.
    Tajima A; Tanaka T; Ebata T; Takeda K; Kawasaki A; Kelly JM; Darcy PK; Vance RE; Raulet DH; Kinoshita K; Okumura K; Smyth MJ; Yagita H
    J Immunol; 2003 Aug; 171(4):1715-21. PubMed ID: 12902470
    [TBL] [Abstract][Full Text] [Related]  

  • 69. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells.
    LeMaoult J; Zafaranloo K; Le Danff C; Carosella ED
    FASEB J; 2005 Apr; 19(6):662-4. PubMed ID: 15670976
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immuno-tolerogenic functions of HLA-G: relevance in transplantation and oncology.
    LeMaoult J; Rouas-Freiss N; Carosella ED
    Autoimmun Rev; 2005 Nov; 4(8):503-9. PubMed ID: 16214086
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HLA class I molecules expression: evaluation of different immunocytochemical methods in malignant lesions.
    Facoetti A; Capelli E; Nano R
    Anticancer Res; 2001; 21(4A):2435-40. PubMed ID: 11724304
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Maternal/fetal interactions: the role of the MHC class I molecule HLA-G.
    Schmidt CM; Orr HT
    Crit Rev Immunol; 1993; 13(3-4):207-24. PubMed ID: 8110376
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Research on HLA-G: an update.
    Favier B; LeMaoult J; Rouas-Freiss N; Moreau P; Menier C; Carosella ED
    Tissue Antigens; 2007 Mar; 69(3):207-11. PubMed ID: 17493143
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Choriocarcinoma cell line resistance to NK lysis mainly involves an HLA-G-independent mechanism.
    Avril T; Jarousseau AC; Watier H; Bardos P; Thibault G
    Transplant Proc; 1999 Jun; 31(4):1866-7. PubMed ID: 10371976
    [No Abstract]   [Full Text] [Related]  

  • 75. Proceedings of the Third International Conference on HLA-G.
    Hum Immunol; 2003 Nov; 64(11):999-1109. PubMed ID: 15307244
    [No Abstract]   [Full Text] [Related]  

  • 76. Modulation of HLA-G antigens expression in myelomonocytic cells.
    Onno M; Le Friec G; Pangault C; Amiot L; Guilloux V; Drénou B; Caulet-Maugendre S; André P; Fauchet R
    Hum Immunol; 2000 Nov; 61(11):1086-94. PubMed ID: 11137211
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms.
    Chang CC; Murphy SP; Ferrone S
    Hum Immunol; 2003 Nov; 64(11):1057-63. PubMed ID: 14602236
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis.
    Riteau B; Rouas-Freiss N; Menier C; Paul P; Dausset J; Carosella ED
    J Immunol; 2001 Apr; 166(8):5018-26. PubMed ID: 11290782
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Functions of nonclassical MHC and non-MHC-encoded class I molecules.
    Braud VM; Allan DS; McMichael AJ
    Curr Opin Immunol; 1999 Feb; 11(1):100-8. PubMed ID: 10047540
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The role of HLA-G in gastrointestinal inflammatory disease and malignancy.
    Downs-Kelly E; Schade AE; Hansel DE
    Semin Cancer Biol; 2007 Dec; 17(6):451-8. PubMed ID: 17716911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.